Freestone Grove Partners LP Invests $368,000 in ICU Medical, Inc. (NASDAQ:ICUI)

Freestone Grove Partners LP purchased a new stake in ICU Medical, Inc. (NASDAQ:ICUI) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 2,371 shares of the medical instruments supplier’s stock, valued at approximately $368,000.

A number of other large investors have also added to or reduced their stakes in the stock. Harvest Fund Management Co. Ltd bought a new stake in shares of ICU Medical during the 4th quarter valued at $33,000. Quarry LP grew its stake in ICU Medical by 764.3% during the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 214 shares in the last quarter. Murphy & Mullick Capital Management Corp acquired a new position in shares of ICU Medical in the 4th quarter valued at approximately $52,000. Venturi Wealth Management LLC raised its position in shares of ICU Medical by 64.0% in the 4th quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock valued at $82,000 after buying an additional 206 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of ICU Medical by 88.8% during the 4th quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 300 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Stock Up 3.4 %

Shares of NASDAQ:ICUI opened at $141.64 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. ICU Medical, Inc. has a 52-week low of $96.97 and a 52-week high of $196.26. The company has a market capitalization of $3.49 billion, a PE ratio of -30.99 and a beta of 0.86. The company has a fifty day moving average of $141.61 and a 200-day moving average of $156.43.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. KeyCorp lowered their price objective on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research report on Monday, April 21st. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Tuesday, April 8th. Finally, Raymond James set a $97.00 target price on ICU Medical in a research note on Wednesday, March 12th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $162.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.